Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,492.73
(
0.72%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.77
(
-0.94%
)
Bitcoin
81,038.87
(
0.68%
)
News Focus
News Focus
Post# of 257553
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122973
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jondoeuk post# 228380

Thursday, 01/23/2020 3:51:20 PM

Thursday, January 23, 2020 3:51:20 PM

Post# of 257553
Re: PD-(L)1 agents for HBV

…I don't think this will be enough and combinations are needed…

No question about that (IMO), but the salient point is that no one will want to administer PD-(L)1 agents indefinitely the way nukes are currently used to treat chronic HBV. Hence, unless PD-(L)1 agents can be a component of some kind of curative regimen, they won’t have any commercial role to play in HBV.

Thanks for the references.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today